Literature DB >> 392960

Risk-benefit stratification as a guide to lidocaine prophylaxis of primary ventricular fibrillation in acute myocardial infarction: an analytic review.

L Goldman, W P Batsford.   

Abstract

Early investigators suggested that ventricular fibrillation without heart failure in acute myocardial infarction was reliably preceded by warning arrhythmias, and that suppression of such arrhythmias with intravenous lidocaine could avoid the need for resuscitation. While the efficacy and safety of lidocaine have been substantiated, the reliability of warning arrhythmias as predictors for primary ventricular fibrillation has not. We present data showing that the risk of primary ventricular fibrillation is most dependent on the patient's age and the interval since the onset of his symptoms, rather than on the presence of warning arrhythmias. We have estimated that lidocaine prophylaxis would have to be given to about 12 patients in the highest risk group (patients under age 50 and within six hours of the onset of symptoms), compared to about 400 patients in the lowest risk group (patients above age 70 and more than 24 hours since the onset of symptoms), to prevent one episode of primary ventricular fibrillation in each group. We propose that these risk stratifications, as adapted to the conditions in specific hospitals, provide the most rational approach to lidocaine prophylaxis of primary ventricular fibrillation.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 392960      PMCID: PMC2595788     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  54 in total

Review 1.  A survey of the coronary care unit: concept and results.

Authors:  T Killip; J T Kimball
Journal:  Prog Cardiovasc Dis       Date:  1968-07       Impact factor: 8.194

2.  Congestive heart failure after acute myocardial infarction.

Authors: 
Journal:  Calif Med       Date:  1971-02

3.  Intensive coronary care--a practical system for a small hospital without house staff.

Authors:  G Church; R O Biern
Journal:  N Engl J Med       Date:  1969-11-20       Impact factor: 91.245

4.  Results of a general hospital coronary care service.

Authors:  B L Pentecost; N M Mayne
Journal:  Br Med J       Date:  1968-03-30

5.  Ventricular tachyarrhythmias and lignocaine prophylaxis in acute myocardial infarction. A clinical and therapeutic study.

Authors:  L Mogensen
Journal:  Acta Med Scand Suppl       Date:  1970

6.  Acute myocardial infarction in the aged: prognosis and management.

Authors:  R Harris; A R Piracha
Journal:  J Am Geriatr Soc       Date:  1970-11       Impact factor: 5.562

7.  Ventricular fibrillation in acute myocardial infarction: prognosis following successful resuscitation.

Authors:  M Stannard; G Sloman
Journal:  Am Heart J       Date:  1969-04       Impact factor: 4.749

8.  Primary ventricular fibrillation complicating acute myocardial infarction.

Authors:  R W Dhurandhar; R L MacMillan; K W Brown
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

9.  Observations on patients with primary ventricular fibrillation complicating acute myocardial infarction.

Authors:  K I Lie; H J Wellens; E Downar; D Durrer
Journal:  Circulation       Date:  1975-11       Impact factor: 29.690

10.  Lignocaine therapy for ventricular ectopic activity after acute myocardial infarction: a double-blind trial.

Authors:  M P Chopra; U Thadani; R W Portal; C P Aber
Journal:  Br Med J       Date:  1971-09-18
View more
  3 in total

Review 1.  Antiarrhythmic prophylaxis after acute myocardial infarction. Is lidocaine still useful?

Authors:  S Nattel; A Arenal
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 2.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 3.  The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.

Authors:  S Nattel; G Gagne; M Pineau
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.